GRACE – Global Resource for Advancing Cancer Education Published on Apr 30, 2018 Dr. Vamsidhar Velcheti, Hematology and Medical Oncology…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 14, 2018 Dr. Sandip Patel, Associate Professor of Medicine…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 14, 2018 Dr. Sandip Patel, Associate Professor of Medicine…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 15, 2018 Dr. H. Jack West, Medical Director, Thoracic…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 14, 2018 Dr. Karen Kelly, Associate Director for Clinical…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 14, 2018 Dr. Sandip Patel, Associate Professor of Medicine…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 17, 2018 Dr. H. Jack West, Medical Director, Thoracic…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 15, 2018 Dr. H. Jack West, Medical Director, Thoracic…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 17, 2018 Dr. H. Jack West, Medical Director, Thoracic…
GRACE – Global Resource for Advancing Cancer Education Published on Oct 17, 2018 Dr. H. Jack West, Medical Director, Thoracic…
GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you…
GRACE – Global Resource for Advancing Cancer Education Published on Apr 15, 2019 For more, please visit http://cancerGRACE.org/. To join…
GRACE – Global Resource for Advancing Cancer Education Published on Jun 26, 2018 Kurtis Davies, PhD, with the University of…
GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options…
Luis G. Paz-Ares, MD, PHD will be presenting Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options…
GRACE – Global Resource for Advancing Cancer Education Published on Dec 17, 2018 GRACE has partnered with Clinical Care Options…
GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you…
GRACE – Global Resource for Advancing Cancer Education Published on Jun 26, 2018 Kurtis Davies, PhD, with the University of…
GRACE – Global Resource for Advancing Cancer Education Published on Jun 26, 2018 Kurtis Davies, PhD, with the University of…
GRACE – Global Resource for Advancing Cancer Education Published on Apr 15, 2019 For more, please visit http://cancerGRACE.org/. To join…
GRACE – Global Resource for Advancing Cancer Education Published on Aug 22, 2018 Drs Zofia Piotrowska, H. Jack West, and…
GRACE – Global Resource for Advancing Cancer EducationPublished on Mar 26, 2019GRACE is excited to bring to you a new…
GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you…
GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you…
Published on Jun 26, 2018 Kurtis Davies, PhD, with the University of Colorado Health Sciences Center Department of Pharmacology, joined…
The Eon Expert Series: Defying Lung Cancer with Eon + Mark Cuban Why does health tech hurt us more than…
Read the full transcription HERE: http://bit.ly/MarkCubanEonExpertSeries A discussion with Mark Cuban and three leading Pulmonologists regarding problems in healthcare technology…
 Philadelphia, PA (May 13, 2019) – Oncoceutics announced today that Michael Chiarella, an industry veteran with more than 20…
UCI team helps uncover how ‘FLASH radiotherapy’ reduces neural cell damage  Irvine, Calif., May 13, 2019 — In hopeful news…
UCI team helps uncover how ‘FLASH radiotherapy’ reduces neural cell damage  Irvine, Calif., May 13, 2019 — In hopeful news…
Philadelphia, PA (May 3, 2019) – Oncoceutics, Inc. announced the publication of two scientific research articles demonstrating that members of…
Composition of Matter Patent and Translational Research Grant issued for ONC213Philadelphia, PA (April 30, 2019) – Oncoceutics, Inc. announced that…
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyonda In Depth, Enhancing Chemo & Radiotherapies.
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyonda & Isoflavonoid Studies.
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyondas Future In NSCLC, Sarcomas & Prostate Cancer.
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Developing Isoflavone Idronoxil For Oncology Purposes.
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the…
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the…
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the…
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the…
Philadelphia, PA (April 24, 2019) – Oncoceutics announced today that Accelerate Brain Cancer Cure (ABC2) has awarded a $116,523 grant…
test video spanish upload
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Engineering EBV Specific T cells.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Mesothelin Targeted CAR-T Study.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses EBV CD19 CAR-T Cells Potency.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Subset Of 11 Mesothelioma Patients.
NEW DATA SHOW BLUEPRINT® IDENTIFIES ESTROGEN RECEPTOR POSITIVE BREAST CANCER PATIENTS WITH POOR RESPONSE TO ANTI-ESTROGEN THERAPY WHO MAY BENEFIT FROM…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of…
Vishwas Paralkar PhD, Cybrexa Chief Scientific Officer Discusses Combining Alphalex Technology With Rucaparib.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses What IRAK4 Degredation Offers.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses The Future Of The IRAK4 Degrader.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses Protein Degradation Technology.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses Elaborating On The IRAK4 Protein Degrader
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses E3 Ligase Atlas In Development.
Toni Choueiri M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Womens Hospital and…
Toni Choueiri M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Womens Hospital and…
Toni Choueiri M.D. Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Womens Hospital and…
David Quinn M.D., PhD Associate Professor of Medicine (Clinical Scholar);Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood…
David Quinn M.D., PhD Associate Professor of Medicine (Clinical Scholar);Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood…
Jose Karam M.D., FACS Associate Professor in the Department of Urology at The University of Texas MD Anderson Cancer Center…
Laurence Albiges M.D., PhD medical oncologist in the Genitourinary group of the Department of Cancer Medicine at the Institute Gustave…
Laurence Albiges M.D., PhD medical oncologist in the Genitourinary group of the Department of Cancer Medicine at the Institute Gustave…
Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Surgical Consequences Of Pretreating Patients With RCC. At…
Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Surgery Or Therapy First. At The Fourteenth European…
Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Elaborating On The CARMENA Trial. At The Fourteenth…
Axel Bex M.D. Department of Urology The Netherlands Cancer Institute Amsterdam Discusses Perioperative Therapy In The CARMENA & PROBE Trials.…
We are pleased to share with you the videos from the live webcast. In this 5th video, the panel opens…
We are pleased to share with you the videos from the live webcast. In this 4th video, Dr. H. Jack…
We are pleased to share with you the videos from the live webcast. In this 3rd video, Dr. Eric Vallieres…
We are pleased to share with you the videos from the live webcast. In this 2nd video, Dr. Puneeth Iyengar…
We are pleased to share with you the videos from the live webcast. In this first video, Dr. West introduces…
Grant Stewart PhD an academic surgeon at the University of Cambridge Discusses Why One Year Of Treatment With Dosing Of…
Grant Stewart PhD an academic surgeon at the University of Cambridge Discusses Elaborating On Multiple Kidney Cancer Studies. At The…
Grant Stewart PhD an academic surgeon at the University of Cambridge Discusses Two IO Plus TKI Studies In Kidney Cancer.…
Alessandro Volpe M.D. of the University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy Discusses Treating Renal Masses…
Alessandro Volpe M.D. of the University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy Discusses Criteria To Indicate…
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses…
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses…
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses…
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses…
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses…
Samra Turajlic M.D. Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma Discusses…
Dr. Ash Tewari discusses the concept of race vs. genetics in Health Disparity research and treatment
Philadelphia, PA (April 9, 2019) – Oncoceutics announced today the publication of an article entitled “First clinical experience with DRD2/3…
Earn CME credit: https://www.naccme.com/program/2018-i7956-1 PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and…
Dr. Ben Levy discusses two trials that are trying to determine if Immunotherapy can help lung cancer patients with earlier…
Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and…
Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon,…
Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1…
Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used…
Earn CME Credit: https://www.naccme.com/program/7327 Knowledge is evolving regarding numerous clinical aspects of immune thrombocytopenic purpura (ITP), and there remains significant…
Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a…
Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used…
Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies…
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as…
Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to…
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1…
Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million…
SOUTH SAN FRANCISCO, Calif., April 2, 2019 /PRNewswire/ –Â ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on the discovery…
April 02, 2019 08:00 ET | Source: Cybrexa Therapeutics   Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in…
Drs. Ben Solomon, Leora Horn, & Jack West assess the utility and limitations of “liquid biopsies”, serum-based testing for molecular…
Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced…
Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation,…
Dr. Seema Nagpal insists on one thing from her lung cancer patients: Proof that they are enjoying their lives. November…
Daniel Goldstein MD Tel Aviv University discusses Moving from Observational Pharmacoeconomics to Interventional Pharmacoeconomics at the Kidney Cancer Association International…
Cristina Suárez MD PhD Hospital Universitari Vall d´Hebron-Vall d´Hebron Institute of Oncology discusses SPAIN: SOGUG MODEL at the Kidney Cancer…
Tim OBrien Vice President of BAUS discusses Centralization of Nephrectomy in the UK The good the bad and the ugly…
Toni K. Choueiri, MD Director, The Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute discusses The Combination of Avelumab +…
Ronan FlippotMD MSc discusses Brain Metastases in Renal Cell CarcinomaAre immune checkpoint inhibitors up to the task? discusses Brain Metastases…
Raquel Perez-Lopez Vall dHebron Institute of Oncology (VHIO)Principal Investigator-Radiomics Group discusses Recist vs iRecist: Clinically Significant? at the Kidney Cancer…
Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of…
Frede Donskov, M.D., DMSc Professor of Oncology Chairman, Kidney Cancer Expert Committee, Danish Medicines Council Aarhus University Hospital Denmark discusses…
Brian i. Rini, MD Cleveland Clinic discusses Axi/Pembro is the Standard of Care in mRCC at the Kidney Cancer Association…
Samra Turajlic The Royal Marsden NHS Foundation Trust, London, UK discusses the second part of A phase II study of…
Dr Pablo Maroto Hospital Sant Pau Barcelona discusses New Network Around Oncologists at the Kidney Cancer Association International Symposium 2019…
Jean-Marie Michot, MD Drug Development Department Gustave Roussy, France jean-marie.michot@gustaveroussy.fr discusses IO toxicities in Kidney Cancer at the Kidney Cancer…
Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology discusses  Update in IO Neoadjuvant (Preoperative)…
Cristina Suárez MD PhD Hospital Universitari Vall d´Hebron-Vall d´Hebron Institute of Oncology discusses NEW TARGETS IN RCC:NKTR at the Kidney…
Brian Shuch, MD Associate Professor of Urology Director, UCLA Kidney Cancer Program Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer…
Monika Wolkers, PhD m.wolkers@sanquin.nl discusses TIL products from Renal Cell Carcinomas are tumor-specific but poor cytokine producers at the Kidney…
Bernadett Szabados of Barts Cancer Institute discusses NEW TARGETS IN RCC at the Kidney Cancer Association International Symposium 2019 in…
Dr. Ross Camidge discusses a clinical trial studying patients with advanced stage lung cancer to identify those who may respond…
Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who…
On this Thanksgiving Day, we salute lung cancer patient Jason Karg and his wife Kristyl for reminding us of the…
Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to…
Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an…
Gratitude is one of the most medicinal emotions we can feel. (Sara Avant Stover) Thank you for joining GRACE in…
As we learn more about immunotherapy for lung cancer, combinations with multiple immunotherapy agents are being explored. Medical oncologist Dr.…
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired…
Drs. Ben Solomon, Leora Horn, & Jack West review whether the data and clinical experience suggest any clinically significant differences…
Drs. Ben Solomon, Leora Horn, & Jack West consider the range of treatment options for patients with an EGFR mutation…
W. Kimryn Rathmell, MD, PhD of Vanderbilt Ingram Cancer Center discusses Novel epigenetic targeting approaches at the Kidney Cancer Association…
Laurence Albiges, Gustave Roussy Villejuif, France discusses HIF-2aa new target in metastatic RCCat the Kidney Cancer Association International Symposium 2019…
Toni K. Choueiri MD of Dana Farber discusses Randomised phase 2 study of sapanisertib (TAK?228/MLN0128) ± TAK-117 versus everolimus in…
Philip Zeuschner, MD of Universität des Saarlandes, Saarbrücken (UKS) discusses Learning curves in 500 robot-assisted partial nephrectomies: the bed-side assistant…
Toni K. Choueiri, MD of Dana-Farber Cancer Institute, Boston, MA discusses A First-in-Human Phase 1/2 Trial of the Oral HIF-2a…
Prof. Alessandro VOLPE University of Eastern Piedmont Maggiore della Carità Hospital, Novara, Italy discusses SMALL RENAL MASSES NON SURGICAL MANAGEMENT…
Manuela Schmidinger, MD, Camillo Porta, MD, Romano Danesi, MD, PhD, Brian I. Rini, MD discuss Optimising advanced RCC treatment: the…
Dr Emmanuel MEYER Department of radiation oncology Centre François Baclesse Caen – France discusses Oligometastatic disease: Localized vs systemic therapy…
Fernando Gómez Muñoz. MD PhD Vascular and Interventional Radiology Hospital Clinic de Barcelona Hospital Sant Joan de Deu, Barcelona Netherlands…
Stereotactic Ablative Body RadioTherapy in Kidney Cancer Ben Vanneste, MD, PhD Radiation-Oncologist, MAASTRO Clinic, The Netherlands discusses Stereotactic Ablative Body…
Dr Kevin Litchfield Kevin.litchfield@crick.ac.uk Twitter: @kevlitchfield discusses Genomic and Transcriptomic Biomarkers of IO Response in RCC at the Kidney Cancer…
Grant D Stewart, MD Surgical Oncology Lead, University Lecturer, University of Cambridge Consultant Urological Surgeon, Addenbrookes Hospital discusses Adjuvant immuno-oncology…
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among…
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a “next generation sequencing”…
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among…
Drs. Leora Horn, Ben Solomon, & Jack West review whether there are specific factors that should make one second generation…
Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in…
Dr. Karen Reckamp of City of Hope Cancer Center reviews the concept of acquired resistance to targeted therapies in patients…
Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of “pseudoprogression”.
Drs. Ben Solomon, Leora Horn, & Jack West compare the clinical data with the third generation EGFR TKIs so active…
Drs. Ben Solomon, Leora Horn, & Jack West discuss whether the data highlighting cognitive deficits from whole brain radiation therapy…
Drs. Ben Solomon, Leora Horn, & Jack West review impressive data demonstrating a striking survival improvement from successful efforts at…
Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance…
James Larkin of the The Royal Marsden NHS Foundation Trust pays tribute to his friend and legendary oncologist Martin Gore…
Thomas Powles Director of Barts Cancer Center. Professor of Urology Cancer, Barts Cancer Institute discusses firist line clear cell RCC:…
W. Kimryn Rathmell, MD, PhD Director of the Division of Hematology and Oncology Vanderbilt University Medical Center discusses Endogenous retrovirus…
Samra Turajlic, MD The Royal Marsden NHS Foundation Trust outlines Cell-free tumour DNA (cfDNA) detection in advanced renal cell carcinoma…
Christopher Wood, MD MD Anderson Cancer Center expresses his thoughts on the late Martin Gore at the Kidney Cancer Association…
David Quinn, MD USC Norris Comprehensive Cancer Center gives a heartfelt tribute to Dr. Martin Gore and his US/International Perspective…
Bernard Escudier of the Institut Gustave Roussy in Villejuif, France reminisces about his late friend Martin Gore at the Kidney…
Tobias Klatte, MD, PhD, FEBU, FRCS(Ed) Consultant Urological Surgeon, Royal Bournemouth Hospital Visiting Researcher, University of Cambridge Honorary Lecturer, University…
This presentation aims to provide an overview of the mRCC patient journey and the challenges clinicians face. To explore how…
John B. Haanen MD PhD Department of Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital asks the question…
Andy Thomas from Kidney Cancer Support Network discusses Cytoreductive Nephrectomy Patient Perspective at the Kidney Cancer Association International Symposium in…
Oncoceutics Expands Patent Family to Include Composition of Matter for ONC206 in Europe  Philadelphia, PA (March 4, 2019) – Oncoceutics, Inc. announced…
Axel Bex Royal Free London NHS Foundation Trust, UCL Division of Surgical and Interventional Science, London, UK and The Netherlands…
Michael Staehler, M.D. Ph.D. Head Interdisciplinary Center on Renal Tumors Department of Urology University of Munich, Germany takes the PROCytoreductive…
Lorenzo Marconi, MD, FEBU Coimbra, Portugal discusses Clinical Marker for Cytoreductive Nephrectomy? at the Kidney Cancer International Symposium in Dubrovnik…
John B. Haanen MD PhD gives the Fitzpatrick Memorial Lecture entitled Do we need a new Carmena in the IO…
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling…
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from…
Dr. West moderates a question & answer session with Drs. Leora Horn and Greg Riely on issues of acquired resistance…
Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also…
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved…
The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates…
Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance…
There are sub-types within the sub-type of EGFR mutation positive lung cancer. In this presentation, Dr. Jack West discusses the…
Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In…
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers…
Following the news on March 19, 2019 that Merck KGaA and Pfizer have discontinued the ongoing Phase III JAVELIN Ovarian…
AUBURNDALE, Mass., March 21, 2019 /PRNewswire/ – Candel Therapeutics (a.k.a. Advantagene, Inc.) announced today the treatment of the first high grade glioma patients in a…
(Kanazawa, 21 March 2019) Researchers at Kanazawa University report in Nature Communications what causes some lung-cancer patients to have an…
March 11, 2019 07:37 PM Eastern Daylight Time  NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced the United States…
On March 8, the FDA granted the accelerated approval of Roche’s programmed cell death protein 1 (PD-1) inhibitor Tecentriq in…
March 18, 2019 BOULDER, Colo., March 18, 2019 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National…
Philadelphia, PA (February 22, 2019) – Oncoceutics, Inc., announces the expansion of its diverse collaborations across the National Institutes of Health…
Read press release online:Â https://ir.moleculin.com/press-releases/detail/117/moleculin-files-with-fda-for-expedited-approval-pathway-for HOUSTON, TX- March 13, 2019 -Â Moleculin Biotech, Inc., (NASDAQ: MBRX)(“Moleculin” or the “Company”), a clinical stage…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Discussing PEDIGREE Study. At The 2019 Genitourinary Cancers Symposium…
Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses Results…
Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses When…
Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses Combining…
Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses Combination…
Sumit K. Subudhi, MD, PhD, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas…
Sumit K. Subudhi, MD, PhD, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas…
Sumit K. Subudhi, MD, PhD, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas…
Bridget F. Koontz, MD, Associate Professor of Radiation Oncology, Duke University School of Medicine, Discusses Moderate Hypofractionation & Ultra-Hypofractionation In…
Bridget F. Koontz, MD, Associate Professor of Radiation Oncology, Duke University School of Medicine, Discusses The Evolving Landscape Of Prostate…
Bridget F. Koontz, MD, Associate Professor of Radiation Oncology, Duke University School of Medicine, Discusses New Guidelines On Hypofractionated EBRT…
Tomasz Beer, MD, Professor of Medicine, Division of Hematology/Medical Oncology, Oregon Health Sciences University, Discusses Recent Data Utilizing LuPSMA In…
Tomasz Beer, MD, Professor of Medicine, Division of Hematology/Medical Oncology, Oregon Health Sciences University, Discusses The ARAMIS Study In nmCRPC…
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses The Evolving Treatment Landscape For Patients…
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses How PSA Is Valuable As A…
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses Data On Racial Differences In Response…
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses Recent Data Examining LuPSMA In Men…
Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses The Implications Of The…
Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses The LATITUDE Study In…
Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses Aramis Study In Prostate…
Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses The ARCHES Trial In…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Challenges Using…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Role Of…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses Molecular Characterization &…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Latest In…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses Outcomes Of KEYNOTE…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses The Evolution Of ADT In Prostate Cancer.…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Impression Of KEYNOTE 365 In mCRPC. At…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Impression Of KEYNOTE 365 In mCRPC. At…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Combination Pembrolizumab And Olaparib In mCRPC. At…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Combining Checkpoint Inhibitors In mCRPC. At The…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Combining Checkpoint Inhibitors In mCRPC. At The…
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses Recent Data Examining Atezolizumab And…
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses The Implications Of CHECKMATE 214…
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses Outcomes Of The KEYNOTE 426…
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses TIVO-3 Study In Highly Refractory…
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses How To Differentiate Between TKIs…
Rana McKay, MD, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, Discusses Next Steps When Treating mRCC…
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical…
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical…
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical…
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical…
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical…
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Phase 2 STREAM Study…
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Opinion On Androgen Receptor…
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Overview Of The ARCHES…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses The Outcomes Of KEYNOTE 426 Presented At GU 2019.…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses How To Treat mRCC After Combination I-O In The…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Intermediate/Poor And Favorable Risk RCC Patients. At The 2019…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Predictive Biomarkers In Selecting Patient Populations For I-O Treatment…
Oncoceutics Licenses Rights to ONC201 for Japan to Ohara Pharmaceutical Co., Ltd. Philadelphia, PA (February 15, 2019) – Oncoceutics, Inc. announced…
Tian Zhang, MD, Assistant Professor of Medicine, Duke Cancer Institute, Discusses Should Patients In The 1st Line Setting Should Receive…